# The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis

> **NCT04134091** · PHASE2 · COMPLETED · sponsor: **Lipocine Inc.** · enrollment: 56 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** LPCN 1144 Formulation A
- **DRUG:** LPCN 1144 Formulation B
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04134091
- **Lead sponsor:** Lipocine Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-27
- **Primary completion:** 2021-06-24
- **Final completion:** 2021-06-24
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04134091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04134091, "The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04134091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*